[go: up one dir, main page]

MX2010004735A - Diva (infeccion diferenciada de animales vacunados) de ehrlichia canis. - Google Patents

Diva (infeccion diferenciada de animales vacunados) de ehrlichia canis.

Info

Publication number
MX2010004735A
MX2010004735A MX2010004735A MX2010004735A MX2010004735A MX 2010004735 A MX2010004735 A MX 2010004735A MX 2010004735 A MX2010004735 A MX 2010004735A MX 2010004735 A MX2010004735 A MX 2010004735A MX 2010004735 A MX2010004735 A MX 2010004735A
Authority
MX
Mexico
Prior art keywords
vaccinated animals
ehrlichia canis
canis diva
canis
differentiate
Prior art date
Application number
MX2010004735A
Other languages
English (en)
Inventor
Eugene Regis Krah Iii
Thomas Patrick O'connor Jr
Melissa Beall
Ramaswamy Chandrashekar
Original Assignee
Idexx Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Lab Inc filed Critical Idexx Lab Inc
Publication of MX2010004735A publication Critical patent/MX2010004735A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona antígenos de Ehrlichia canis que se pueden usar para detectar animales infectados por E. canis a pesar de que los animales hayan sido vacunados o no contra E. canis. La invención proporciona también composiciones y métodos para determinar la presencia de antígenos y anticuerpos de E. canis.
MX2010004735A 2007-10-31 2008-10-31 Diva (infeccion diferenciada de animales vacunados) de ehrlichia canis. MX2010004735A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98401907P 2007-10-31 2007-10-31
PCT/US2008/082038 WO2009059170A2 (en) 2007-10-31 2008-10-31 Ehrlichia canis diva (differentiate infection from vaccinated animals)

Publications (1)

Publication Number Publication Date
MX2010004735A true MX2010004735A (es) 2010-05-20

Family

ID=40583129

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004735A MX2010004735A (es) 2007-10-31 2008-10-31 Diva (infeccion diferenciada de animales vacunados) de ehrlichia canis.

Country Status (9)

Country Link
US (2) US7888054B2 (es)
EP (3) EP2664344B1 (es)
JP (2) JP5759724B2 (es)
KR (2) KR20160003306A (es)
BR (1) BRPI0819349B1 (es)
CA (1) CA2703989C (es)
ES (3) ES2724806T3 (es)
MX (1) MX2010004735A (es)
WO (1) WO2009059170A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842473B2 (en) * 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
WO2008137881A2 (en) 2007-05-04 2008-11-13 The Ohio State University Research Foundation Ehrlichia ewingii proteins, nucleic acids, and methods of their use
MX2010004735A (es) * 2007-10-31 2010-05-20 Idexx Lab Inc Diva (infeccion diferenciada de animales vacunados) de ehrlichia canis.
SMT202500126T1 (it) 2008-12-09 2025-05-12 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
ES2596952T3 (es) 2009-11-20 2017-01-13 Abaxis, Inc. Péptidos, dispositivos y procedimientos para la detección de anticuerpos de Ehrlichia
US20140162256A1 (en) 2011-03-31 2014-06-12 Yasuko Rikihisa Compositions and methods for the detection of anaplasma platys
WO2014059274A1 (en) 2012-10-11 2014-04-17 Abaxis, Inc. Peptides, devices, and methods for the detection of ehrlichia antibodies
EP2925352B1 (en) 2012-12-03 2019-10-02 Ohio State Innovation Foundation Ehrlichial invasin for immunization, diagnosis, and cell delivery
US9442112B2 (en) 2014-04-04 2016-09-13 Abaxis, Inc. Compositions and methods for identifying Ehrlichia species
JP6799927B2 (ja) * 2016-02-23 2020-12-16 古河電気工業株式会社 生体分子検出用試験キット、及びこれを用いた生体分子の検出方法、並びにこれらに用いられる生体分子検出用標識試薬
US10626468B2 (en) 2016-09-12 2020-04-21 Delta Electronics Int'l (Singapore) Pte Ltd Primer pair, kit and method for detecting Ehrlichia canis
KR102110733B1 (ko) 2018-07-16 2020-05-14 (주)아이씨엔캐스트 블록체인 기반의 콘텐츠 리워드 제공 방법 및 시스템

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4894576A (en) 1987-04-10 1990-01-16 Clarion Co., Ltd. Surface-acoustic-wave convolver
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5726010A (en) 1991-07-31 1998-03-10 Idexx Laboratories, Inc. Reversible flow chromatographic binding assay
AU7208698A (en) 1997-03-24 1998-10-20 Merial Canine ehrlichiosis immunogenic and diagnostic compositions and methods
US6043085A (en) 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
US20020115840A1 (en) 1998-11-30 2002-08-22 Walker David H. Homologous 28-kilodaltion immunodominant protein genes of Ehrlichia canis and uses thereof
US6458942B1 (en) 1998-11-30 2002-10-01 Research Development Foundation 28-kDa immunoreactive protein gene of Ehrlichia canis and uses thereof
US6392023B1 (en) 1999-03-03 2002-05-21 Research Development Foundation Homologous 28-kilodalton immunodominant protein genes of Ehrlicha canis and uses thereof
US7335754B2 (en) 1999-07-21 2008-02-26 Cornell Research Foundation, Inc. Ehrlichia canis genes and vaccines
US6355777B1 (en) 2000-04-28 2002-03-12 Research Development Foundation P43 antigen for the immunodiagnosis of canine ehrlichiosis and uses thereof
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7087372B2 (en) * 2001-01-18 2006-08-08 Idexx Laboratories, Inc. Compositions and methods for detection of Ehrlichia canis and Ehrlichia chaffeensis antibodies
US7183060B2 (en) * 2005-02-22 2007-02-27 Idexx Laboratories, Inc. Peptides for detection of antibody to Ehrlichia ewingii
US7407770B2 (en) 2001-01-18 2008-08-05 Idexx Corporation Compositions and methods for detection of Ehrlichia canis and Ehrlichia chaffeensis antibodies
CA2466156C (en) 2001-11-01 2013-01-15 Research Development Foundation Ehrlichia disulfide bond formation proteins and uses thereof
CN100386430C (zh) * 2002-11-04 2008-05-07 研究发展基金会 用于犬和人埃利希病的免疫诊断的p153和p156抗原及其用途
US7722880B2 (en) 2004-02-25 2010-05-25 Research Development Foundation Immunoreactive 38-KDA ferric binding protein of ehrlichia canis and uses thereof
CA2571452A1 (en) 2004-06-18 2006-01-26 Regents Of The University Of Minnesota Identifying virally infected and vaccinated organisms
US7842474B2 (en) * 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
US7842473B2 (en) * 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
MX2007016189A (es) 2005-06-16 2008-03-10 Res Dev Foundation Ortologos de proteinas inmunoreactivas de ehrlichia canis y e. chaffeensis.
CN101203449B (zh) 2006-07-06 2012-01-04 三菱电机株式会社 电梯的显示装置
EP2064231B2 (en) 2006-08-31 2020-08-26 Research Development Foundation Immunoreactive glycoprotein gp19 of ehrlichia canis
KR100814681B1 (ko) * 2007-06-25 2008-03-18 이수인 (주) 넘침 방지 보조수조를 갖는 양변기
MX2010004735A (es) * 2007-10-31 2010-05-20 Idexx Lab Inc Diva (infeccion diferenciada de animales vacunados) de ehrlichia canis.

Also Published As

Publication number Publication date
ES2913324T3 (es) 2022-06-01
EP2215477A2 (en) 2010-08-11
JP5759724B2 (ja) 2015-08-05
EP2215477A4 (en) 2010-12-29
EP3527221A1 (en) 2019-08-21
JP2015038476A (ja) 2015-02-26
JP2011504582A (ja) 2011-02-10
EP2664344B1 (en) 2019-02-27
ES2724806T3 (es) 2019-09-16
WO2009059170A9 (en) 2010-06-03
CA2703989C (en) 2020-12-22
EP2215477B1 (en) 2019-01-16
KR20100102597A (ko) 2010-09-24
EP3527221B1 (en) 2022-02-23
US20110182925A1 (en) 2011-07-28
KR101621038B1 (ko) 2016-05-16
US8980274B2 (en) 2015-03-17
EP2664344A1 (en) 2013-11-20
KR20160003306A (ko) 2016-01-08
WO2009059170A2 (en) 2009-05-07
BRPI0819349B1 (pt) 2018-05-08
CA2703989A1 (en) 2009-05-07
ES2720363T3 (es) 2019-07-19
US20090110691A1 (en) 2009-04-30
WO2009059170A3 (en) 2010-02-18
US7888054B2 (en) 2011-02-15

Similar Documents

Publication Publication Date Title
MX2010004735A (es) Diva (infeccion diferenciada de animales vacunados) de ehrlichia canis.
WO2008043000A3 (en) Ehrlicia canis diva (differentiate infected from vaccinated animals)
EA201270149A1 (ru) Ингибиторы bace
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
MX337591B (es) Dispositivo para la deteccion de antigenos y usos del mismo.
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
MX382826B (es) Anticuerpos dkk1 y metodos de uso.
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
PH12013501339A1 (en) Anti-pcsk9 antibodies and methods of use
EA201201000A1 (ru) Способы лечения колоректального рака
ES2570380T3 (es) Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
EA201291105A1 (ru) Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
IN2013MN00501A (es)
MY154713A (en) Device for identifying oral conditions
PH12013500616A1 (en) Antibody compositions and methods of use
MX336109B (es) Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
IN2012DN03338A (es)
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
MX2012011829A (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
WO2006107924A3 (en) Ehrlichia canis diva (differentiate infected from vaccinated animals)
ATE549031T1 (de) Impfstoffzusammensetzung zur prävention von cmv- infektionen
SG178596A1 (en) Methods of treatment using anti-oxidized ldl antibodies

Legal Events

Date Code Title Description
FG Grant or registration